Indivior Pharmaceuticals — Business Overview
What does Indivior do?
Indivior is a specialty pharmaceutical company entirely focused on treating opioid use disorder (OUD), a chronic brain disease characterized by compulsive opioid use. It develops and sells medications that help patients manage cravings, block the effects of opioids, and stay in recovery. The company describes itself as the market leader in long-acting injectable (LAI) treatments for OUD — meaning drugs delivered by injection that work over weeks or months rather than requiring a daily pill or film.
Indivior's product lineup is small and tightly focused on two actively promoted treatments:
| Product | Type | How It Works | Key Markets | 2025 Net Sales |
|---|---|---|---|---|
| SUBLOCADE | Monthly injectable buprenorphine | Injected by a healthcare provider once a month; delivers sustained buprenorphine levels | U.S., Canada, Australia | $856 million |
| SUBOXONE Film | Sublingual (under-the-tongue) film combining buprenorphine and naloxone | Dissolves under the tongue or against the cheek; patient self-administers | U.S., Canada, Australia | $346 million |
| SUBUTEX Tablet | Sublingual buprenorphine tablet | Older formulation; no longer sold in the U.S. | Australia, France, Germany | Included above |
SUBLOCADE is the company's growth engine and became its largest revenue product in 2022. SUBOXONE Film is a mature, declining product facing generic competition in the U.S. The company has 838 employees worldwide as of December 31, 2025.
How does Indivior make money?
Indivior sells prescription pharmaceuticals directly to specialty pharmacies, specialty distributors, and wholesale pharmaceutical companies, who in turn supply hospitals, clinics, and healthcare providers. Because SUBLOCADE must be administered by a healthcare professional (it cannot be dispensed directly to patients), it flows through a tightly controlled specialty distribution network. SUBOXONE Film, by contrast, can be dispensed to patients at regular pharmacies.
Revenue is highly concentrated in the U.S., which accounted for 85% of net revenues in both 2025 and 2024. Three large U.S. wholesale pharmaceutical companies together represented 51% of global net revenues in 2025 — though their relative importance is declining as SUBLOCADE (sold through specialty channels) grows. The largest single customer accounted for 20% of net revenues in 2025. A significant share of patients are covered by Medicaid (the U.S. government healthcare program for lower-income individuals), which is notable because OUD disproportionately affects people who are unemployed or lack employer-sponsored insurance. Over 88% of insured lives in the U.S. have coverage for SUBLOCADE, and over 95% of enrolled patients pay $0 out of pocket through the company's co-pay assistance program.
What market does Indivior operate in?
Indivior operates in the market for medication for opioid use disorder (MOUD), a subset of the broader addiction medicine and specialty pharmaceutical industry. The scale of the underlying problem is significant: in the U.S. alone in 2024, approximately 4.8 million people aged 12 and older had OUD, yet only 17% of them — roughly 818,000 people — received any medication treatment. Globally, 64 million people live with a substance use disorder, up 13% over the past decade, and opioids are responsible for about two-thirds of drug-related deaths worldwide.
Several secular trends favor this market. The fentanyl crisis continues to drive overdose deaths in the U.S. — approximately 47,000 opioid overdose deaths in the 12 months ending August 2025, with fentanyl involved in 96% of those fatalities. Growing recognition that OUD is a chronic disease (not a moral failing), expanding Medicaid coverage, and policy pressure to increase access to treatment all support demand for MOUD products. The 2025 FDA label update allowing SUBLOCADE to be started on Day 1 of treatment (rather than requiring a waiting period) may also reduce a key practical barrier to adoption.
Who are Indivior's main competitors?
The competitive picture differs sharply between SUBLOCADE and SUBOXONE Film. SUBLOCADE, as a patented monthly LAI, faces one direct branded competitor: BRIXADI (buprenorphine LAI), made by Camurus and marketed in the U.S. by Braeburn. Outside the U.S., Camurus's equivalent product, BUVIDAL, has first-mover advantage in most markets including Australia, where it is well established. SUBLOCADE's U.S. patents run through various dates, with several extending to 2031–2044, providing meaningful protection for now.
SUBOXONE Film, by contrast, is under heavy generic pressure. Four generic competitors sell buprenorphine/naloxone film in the U.S., and Indivior's share of the sublingual film category has fallen to an average of 14.2% in 2025. The company stopped actively promoting SUBOXONE Film in the U.S. in 2020 as part of its settlement with the Department of Justice and no longer deploys a sales force behind it, though it remains available. In older tablet formulations (SUBUTEX and SUBOXONE tablets sold in Europe), generic versions have been available since 2010 and 2018, respectively. The broader MOUD market also competes against methadone programs, which are historically entrenched. Indivior's claimed advantages for SUBLOCADE center on its once-monthly dosing, reduced diversion risk (it cannot be extracted once injected), and clinical data showing better patient retention versus oral alternatives.
Where does Indivior operate?
Indivior is primarily a U.S.-focused business. The U.S. generated 85% of net revenues in 2025, and the company says an even larger share of its profitability comes from the U.S. market. Of its 838 employees, 593 (71%) are based in the U.S., with headquarters in North Chesterfield, Virginia.
Outside the U.S., the company is actively consolidating its international footprint. In October 2025, Indivior announced it would exit the U.K., Ireland, Sweden, Israel, Finland, and Italy. Going forward, it plans to maintain commercial operations only in Canada and Australia, retain a presence in France, and continue selling (without local operations) in Germany. Canada and Australia are the next most meaningful markets, though the filing does not break out their individual revenue contributions separately.
Manufacturing is split between the U.K. and the U.S. The active pharmaceutical ingredient (buprenorphine) is manufactured at Indivior's Fine Chemical Plant in Hull, UK, which produces API for all its products. SUBLOCADE itself is currently contract-manufactured by Curia (a contract manufacturer), though Indivior is investing in its Raleigh, North Carolina facility to bring SUBLOCADE manufacturing in-house over time. SUBOXONE Film is manufactured exclusively by Aquestive Therapeutics at two facilities in Portage, Indiana. The continued reliance on the Hull plant for API — while the company has redomiciled to the U.S. and is shrinking its non-U.S. operations — represents a supply chain dependency worth monitoring.